Sexually Transmitted Disease Surveillance 1998 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report – 1998
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

Sexually Transmitted Disease Surveillance 1998 Supplement: Gonococcal Isolate Surveillance Project (GISP) Annual Report – 1998

Filetype[PDF-766.14 KB]


English

Details:

  • Alternative Title:
    Gonococcal Isolate Surveillance Project (GISP) annual report, 1998;GISP 1998 surveillance supplement;
  • Personal Author:
  • Corporate Authors:
  • Description:
    "Gonorrhea is the second most frequently reported communicable disease in the United States. Overall gonorrhea rates in the United States declined 72% since 1975. However, between 1997 and 1998, the rate increased by 8.9% from 122.0 cases per 100,000 persons to 132.9. Gonorrhea rates remain high in the southeastern states, among minorities, and among adolescents of all racial and ethnic groups. The health impact of gonorrhea is largely related to its role as a major cause of pelvic inflammatory disease, which frequently leads to infertility or ectopic pregnancy.2 In addition, recent data suggest that gonorrhea facilitates HIV transmission. Control of gonorrhea has been complicated by the development of resistance to antimicrobial agents. The appearance of penicillinase-producing Neisseria gonorrhoeae (PPNG) and chromosomally mediated penicillin- and tetracycline-resistant N. gonorrhoeae (CMRNG) in the 1970s eventually led to the abandonment of these drugs as therapies for gonorrhea. The currently recommended primary therapies for gonorrhea are two broad-spectrum cephalosporins, ceftriaxone and cefixime, and two fluoroquinolones, ciprofloxacin and ofloxacin.5 However, fluoroquinolone-resistant N. gonorrhoeae have been reported from many parts of the world, including the United States." -- p. 1.
  • Content Notes:
    Division of STD Prevention, prepared by Susan A. Wang, Jester Harvey, William C. Levine, Joan S. Knapp, David L. Trees, Manhar Parekh and Sandra W. Neal.

    "November 1999."

    Also available via the World Wide Web.

    Includes bibliographical references (p. 5-6).

  • Subjects:
  • Document Type:
  • Name as Subject:
  • Genre:
  • Place as Subject:
  • Pages in Document:
    print; [4], 2-17 p. : ill., maps ; 28 cm.
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

  • No Additional Files
More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov